Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 44 | 2024 | 176 | 14.570 |
Why?
|
| Cytomegalovirus Infections | 13 | 2017 | 25 | 4.530 |
Why?
|
| Killer Cells, Natural | 12 | 2023 | 33 | 4.330 |
Why?
|
| T-Lymphocytes | 12 | 2022 | 48 | 4.110 |
Why?
|
| Humans | 61 | 2024 | 5477 | 2.550 |
Why?
|
| Aging | 7 | 2016 | 127 | 2.520 |
Why?
|
| Adult | 38 | 2021 | 1683 | 2.440 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2023 | 37 | 2.380 |
Why?
|
| Male | 41 | 2024 | 2765 | 2.300 |
Why?
|
| Monocytes | 6 | 2018 | 18 | 2.090 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2024 | 11 | 2.090 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2018 | 17 | 1.900 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2020 | 14 | 1.650 |
Why?
|
| Space Flight | 5 | 2020 | 26 | 1.650 |
Why?
|
| Female | 26 | 2021 | 2811 | 1.580 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2020 | 21 | 1.510 |
Why?
|
| Immune System | 5 | 2016 | 12 | 1.400 |
Why?
|
| Neoplasms | 3 | 2020 | 99 | 1.400 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 2 | 2021 | 5 | 1.360 |
Why?
|
| Cytomegalovirus | 5 | 2017 | 12 | 1.360 |
Why?
|
| Multiple Myeloma | 3 | 2015 | 10 | 1.320 |
Why?
|
| Virus Latency | 3 | 2020 | 6 | 1.280 |
Why?
|
| Physical Fitness | 3 | 2015 | 22 | 1.250 |
Why?
|
| Cellular Senescence | 5 | 2013 | 14 | 1.200 |
Why?
|
| Cytokines | 4 | 2020 | 37 | 1.150 |
Why?
|
| Bisoprolol | 4 | 2021 | 9 | 1.140 |
Why?
|
| Nadolol | 4 | 2021 | 10 | 1.130 |
Why?
|
| Young Adult | 16 | 2020 | 850 | 1.090 |
Why?
|
| Up-Regulation | 2 | 2024 | 30 | 1.030 |
Why?
|
| Leukemia | 2 | 2024 | 7 | 1.010 |
Why?
|
| Military Personnel | 3 | 2020 | 23 | 0.980 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2016 | 8 | 0.950 |
Why?
|
| Flow Cytometry | 11 | 2018 | 40 | 0.940 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 4 | 0.920 |
Why?
|
| Immunity | 2 | 2015 | 9 | 0.880 |
Why?
|
| Virus Activation | 3 | 2020 | 5 | 0.880 |
Why?
|
| Lymphoma | 2 | 2015 | 5 | 0.870 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2024 | 2 | 0.870 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2021 | 10 | 0.850 |
Why?
|
| Immunity, Cellular | 2 | 2015 | 4 | 0.840 |
Why?
|
| Weight-Bearing | 2 | 2016 | 17 | 0.830 |
Why?
|
| Cell Differentiation | 5 | 2015 | 75 | 0.820 |
Why?
|
| Exercise Test | 5 | 2016 | 43 | 0.810 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 2 | 2020 | 5 | 0.810 |
Why?
|
| Phenotype | 8 | 2020 | 73 | 0.800 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2020 | 19 | 0.800 |
Why?
|
| Herpesviridae Infections | 2 | 2020 | 4 | 0.800 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2024 | 6 | 0.790 |
Why?
|
| Running | 3 | 2021 | 16 | 0.790 |
Why?
|
| Lactic Acid | 3 | 2020 | 9 | 0.780 |
Why?
|
| Oxygen Consumption | 4 | 2018 | 24 | 0.780 |
Why?
|
| Middle Aged | 11 | 2020 | 1098 | 0.750 |
Why?
|
| Weightlessness | 1 | 2022 | 15 | 0.750 |
Why?
|
| Saliva | 2 | 2019 | 20 | 0.730 |
Why?
|
| Stress, Physiological | 2 | 2019 | 28 | 0.730 |
Why?
|
| Bicycling | 3 | 2021 | 7 | 0.720 |
Why?
|
| Lymphocytes | 2 | 2018 | 9 | 0.700 |
Why?
|
| Time Factors | 7 | 2020 | 176 | 0.700 |
Why?
|
| Adoptive Transfer | 2 | 2018 | 4 | 0.700 |
Why?
|
| Erythropoietin | 1 | 2021 | 3 | 0.700 |
Why?
|
| High-Intensity Interval Training | 1 | 2021 | 1 | 0.690 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2021 | 2 | 0.690 |
Why?
|
| Physical Endurance | 1 | 2021 | 9 | 0.690 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 3 | 0.670 |
Why?
|
| Trans-Activators | 4 | 2016 | 19 | 0.670 |
Why?
|
| Antiviral Agents | 1 | 2020 | 17 | 0.660 |
Why?
|
| Viruses | 1 | 2020 | 12 | 0.660 |
Why?
|
| Walking | 4 | 2020 | 53 | 0.660 |
Why?
|
| Graft vs Tumor Effect | 1 | 2020 | 2 | 0.640 |
Why?
|
| Receptors, Adrenergic | 1 | 2020 | 3 | 0.640 |
Why?
|
| Herpesviridae | 1 | 2020 | 3 | 0.640 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2019 | 7 | 0.630 |
Why?
|
| Heart Rate | 3 | 2020 | 43 | 0.630 |
Why?
|
| Herpesvirus 4, Human | 2 | 2016 | 3 | 0.600 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 107 | 0.600 |
Why?
|
| Adenoviridae | 1 | 2018 | 2 | 0.570 |
Why?
|
| Dendritic Cells | 2 | 2015 | 10 | 0.570 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2023 | 15 | 0.570 |
Why?
|
| Cell Survival | 1 | 2018 | 57 | 0.560 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 3 | 0.550 |
Why?
|
| Lectins, C-Type | 3 | 2014 | 6 | 0.550 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 175 | 0.550 |
Why?
|
| Animals | 6 | 2024 | 1817 | 0.530 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2023 | 15 | 0.530 |
Why?
|
| Immunosenescence | 2 | 2018 | 3 | 0.520 |
Why?
|
| Herpes Simplex | 2 | 2014 | 7 | 0.510 |
Why?
|
| Mice | 4 | 2024 | 719 | 0.500 |
Why?
|
| Receptors, KIR2DL1 | 2 | 2015 | 2 | 0.480 |
Why?
|
| Inflammation | 1 | 2016 | 59 | 0.480 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 5 | 0.470 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 5 | 0.470 |
Why?
|
| Survivors | 1 | 2015 | 17 | 0.460 |
Why?
|
| Energy Metabolism | 1 | 2015 | 18 | 0.460 |
Why?
|
| Physical Exertion | 2 | 2016 | 9 | 0.460 |
Why?
|
| Leukocyte Count | 4 | 2018 | 9 | 0.460 |
Why?
|
| Immunotherapy | 1 | 2015 | 22 | 0.460 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2015 | 2 | 0.450 |
Why?
|
| Astronauts | 3 | 2019 | 20 | 0.450 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 9 | 0.450 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 18 | 0.450 |
Why?
|
| Lymphocyte Activation | 4 | 2020 | 15 | 0.430 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 3 | 0.430 |
Why?
|
| Coinfection | 1 | 2014 | 4 | 0.430 |
Why?
|
| Virus Diseases | 1 | 2013 | 2 | 0.410 |
Why?
|
| Immunity, Innate | 1 | 2013 | 8 | 0.410 |
Why?
|
| Athletes | 4 | 2018 | 8 | 0.410 |
Why?
|
| Telomere | 2 | 2010 | 5 | 0.400 |
Why?
|
| Healthy Volunteers | 3 | 2018 | 42 | 0.400 |
Why?
|
| Antigens, Surface | 2 | 2011 | 4 | 0.380 |
Why?
|
| Cold Temperature | 1 | 2011 | 4 | 0.360 |
Why?
|
| Cells, Cultured | 3 | 2018 | 134 | 0.350 |
Why?
|
| Biomarkers | 4 | 2019 | 87 | 0.340 |
Why?
|
| Hydrocortisone | 2 | 2020 | 18 | 0.320 |
Why?
|
| Adaptive Immunity | 1 | 2009 | 1 | 0.320 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 31 | 0.320 |
Why?
|
| Exercise Therapy | 3 | 2021 | 28 | 0.320 |
Why?
|
| Catecholamines | 2 | 2020 | 8 | 0.310 |
Why?
|
| Cell Proliferation | 2 | 2020 | 120 | 0.310 |
Why?
|
| Cell Movement | 1 | 2010 | 64 | 0.310 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2016 | 4 | 0.310 |
Why?
|
| Anaerobic Threshold | 3 | 2016 | 7 | 0.300 |
Why?
|
| HLA-DR Antigens | 1 | 2008 | 1 | 0.300 |
Why?
|
| Toll-Like Receptors | 1 | 2008 | 4 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 16 | 0.290 |
Why?
|
| Interleukin-2 | 2 | 2022 | 4 | 0.290 |
Why?
|
| United Kingdom | 4 | 2020 | 9 | 0.280 |
Why?
|
| Double-Blind Method | 2 | 2018 | 34 | 0.280 |
Why?
|
| Receptors, Immunologic | 3 | 2014 | 9 | 0.280 |
Why?
|
| Immunoglobulin A, Secretory | 2 | 2019 | 4 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2017 | 4 | 0.270 |
Why?
|
| Muramidase | 2 | 2019 | 33 | 0.270 |
Why?
|
| Lymphocyte Count | 3 | 2017 | 5 | 0.250 |
Why?
|
| K562 Cells | 2 | 2018 | 10 | 0.250 |
Why?
|
| Signal Transduction | 2 | 2018 | 225 | 0.240 |
Why?
|
| Viral Matrix Proteins | 2 | 2016 | 4 | 0.240 |
Why?
|
| Phosphoproteins | 2 | 2016 | 17 | 0.240 |
Why?
|
| Cell Count | 2 | 2015 | 33 | 0.230 |
Why?
|
| Interleukin-10 | 2 | 2017 | 9 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 1 | 2024 | 6 | 0.220 |
Why?
|
| Aged | 5 | 2019 | 859 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 34 | 0.210 |
Why?
|
| CD57 Antigens | 2 | 2015 | 2 | 0.210 |
Why?
|
| Mice, Inbred Strains | 1 | 2023 | 7 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 3 | 0.200 |
Why?
|
| Age Factors | 2 | 2013 | 75 | 0.200 |
Why?
|
| Transcriptome | 1 | 2023 | 47 | 0.200 |
Why?
|
| Blood Pressure | 2 | 2020 | 40 | 0.190 |
Why?
|
| Cell Separation | 3 | 2018 | 7 | 0.190 |
Why?
|
| Linear Models | 2 | 2013 | 60 | 0.180 |
Why?
|
| Models, Biological | 2 | 2015 | 131 | 0.180 |
Why?
|
| Foot | 2 | 2020 | 8 | 0.170 |
Why?
|
| Species Specificity | 1 | 2020 | 15 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2020 | 8 | 0.170 |
Why?
|
| Adolescent | 3 | 2013 | 806 | 0.160 |
Why?
|
| Plyometric Exercise | 1 | 2020 | 1 | 0.160 |
Why?
|
| Shoes | 1 | 2020 | 2 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2020 | 3 | 0.160 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 7 | 0.160 |
Why?
|
| DNA, Viral | 1 | 2020 | 7 | 0.160 |
Why?
|
| Virus Shedding | 1 | 2019 | 2 | 0.160 |
Why?
|
| Peptides | 1 | 2020 | 51 | 0.160 |
Why?
|
| Cathelicidins | 1 | 2019 | 6 | 0.160 |
Why?
|
| alpha-Amylases | 1 | 2019 | 3 | 0.160 |
Why?
|
| Cell Line | 1 | 2020 | 86 | 0.160 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 2 | 0.150 |
Why?
|
| Immunity, Humoral | 1 | 2018 | 2 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2018 | 3 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2018 | 7 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2019 | 21 | 0.150 |
Why?
|
| Granulocytes | 1 | 2018 | 3 | 0.140 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2017 | 2 | 0.140 |
Why?
|
| Antigens, CD34 | 1 | 2017 | 3 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 4 | 0.140 |
Why?
|
| Lymphocytosis | 1 | 2017 | 2 | 0.130 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 4 | 0.130 |
Why?
|
| Neutrophils | 1 | 2016 | 19 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 17 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2016 | 11 | 0.120 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2015 | 2 | 0.120 |
Why?
|
| Leukocytes | 1 | 2015 | 6 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 2 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 44 | 0.120 |
Why?
|
| Survival Rate | 1 | 2015 | 16 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2016 | 100 | 0.120 |
Why?
|
| Dextrans | 1 | 2015 | 4 | 0.110 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2015 | 4 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2015 | 8 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2015 | 1 | 0.110 |
Why?
|
| Motor Activity | 2 | 2016 | 66 | 0.110 |
Why?
|
| alpha-Defensins | 1 | 2015 | 2 | 0.110 |
Why?
|
| Salivary alpha-Amylases | 1 | 2015 | 2 | 0.110 |
Why?
|
| Lactoferrin | 1 | 2015 | 3 | 0.110 |
Why?
|
| Norepinephrine | 1 | 2015 | 4 | 0.110 |
Why?
|
| WT1 Proteins | 1 | 2015 | 3 | 0.110 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2015 | 3 | 0.110 |
Why?
|
| Hormones | 1 | 2015 | 5 | 0.110 |
Why?
|
| Epinephrine | 1 | 2015 | 8 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 6 | 0.110 |
Why?
|
| Antigen Presentation | 1 | 2015 | 7 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 5 | 0.110 |
Why?
|
| Cyclic AMP | 1 | 2015 | 11 | 0.110 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 26 | 0.110 |
Why?
|
| Sleep Deprivation | 1 | 2015 | 10 | 0.110 |
Why?
|
| Health | 1 | 2014 | 4 | 0.110 |
Why?
|
| Serologic Tests | 1 | 2014 | 3 | 0.110 |
Why?
|
| CD4-CD8 Ratio | 1 | 2014 | 3 | 0.110 |
Why?
|
| CD3 Complex | 1 | 2014 | 5 | 0.110 |
Why?
|
| CD28 Antigens | 1 | 2014 | 5 | 0.110 |
Why?
|
| Space Simulation | 1 | 2014 | 2 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2014 | 32 | 0.100 |
Why?
|
| Parvovirus B19, Human | 1 | 2013 | 2 | 0.100 |
Why?
|
| Simplexvirus | 1 | 2013 | 5 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 14 | 0.100 |
Why?
|
| Prognosis | 1 | 2013 | 59 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2013 | 96 | 0.100 |
Why?
|
| Interleukin-4 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Interferon-gamma | 1 | 2012 | 7 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 14 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2014 | 88 | 0.100 |
Why?
|
| Physiology | 1 | 2012 | 2 | 0.090 |
Why?
|
| Oxygen | 1 | 2012 | 21 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 5 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 19 | 0.090 |
Why?
|
| Body Composition | 1 | 2011 | 16 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2011 | 31 | 0.090 |
Why?
|
| Thymus Gland | 1 | 2011 | 2 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2011 | 49 | 0.090 |
Why?
|
| Apoptosis | 1 | 2011 | 55 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 16 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2009 | 49 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 1 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Receptors, IgG | 1 | 2008 | 4 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 12 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 81 | 0.070 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 4 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 13 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2023 | 119 | 0.050 |
Why?
|
| Jogging | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2020 | 2 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2020 | 176 | 0.040 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2018 | 2 | 0.040 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2018 | 2 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 4 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 3 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 10 | 0.040 |
Why?
|
| Homeostasis | 1 | 2018 | 30 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 26 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 72 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2019 | 132 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2018 | 4 | 0.040 |
Why?
|
| Quality of Life | 1 | 2019 | 117 | 0.030 |
Why?
|
| Hand Strength | 1 | 2019 | 90 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 80 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 9 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 24 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 97 | 0.030 |
Why?
|
| Smoking | 1 | 2016 | 94 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 350 | 0.030 |
Why?
|
| Risk Factors | 1 | 2016 | 184 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 1 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 5 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 14 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 25 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 19 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2015 | 29 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2015 | 131 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2015 | 212 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2014 | 29 | 0.030 |
Why?
|
| Sex Factors | 1 | 2013 | 81 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 2012 | 4 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 11 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2012 | 8 | 0.020 |
Why?
|
| Biological Transport | 1 | 2012 | 19 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2012 | 13 | 0.020 |
Why?
|